Enanta Pharmaceuticals Appoints Mark Foletta to its Board of Directors
July 10, 2020 at 06:13 pm IST
Share
Enanta Pharmaceuticals reported the appointment of Mark G. Foletta to its Board of Directors. Foletta will also serve as the Chair of the Audit Committee and will be a member of the Nominating and Corporate Governance Committee. The appointment of Foletta increases the number of Enanta Directors to seven. Most recently, Foletta was Executive Vice President and Chief Financial Officer of Tocagen, a clinical-stage biopharmaceutical company focused on advancing a cancer-selective gene therapy platform, prior to its merger with Forte Biosciences.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).